ReviewDiabetology & metabolic syndrome2025
The impact of sertraline treatment on obesity, inflammation, blood pressure, and lipid profiles: a systematic review and meta-analysis of randomized controlled trials.
Review in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSertraline, a commonly prescribed selective serotonin reuptake inhibitor (SSRI), is widely used for the treatment of depression. While its psychotropic benefits are well established, its effects on metabolic and cardiovascular health remain uncertain. This systematic review and meta-analysis aimed to evaluate the impact of sertraline on obesity, inflammation, glycemic control, blood pressure, and lipid profiles in adults.
methodsA comprehensive literature search was conducted across five databases through August 2025. A total of 16 studies comprising 17 intervention arms were included. Data were synthesized using a random-effects model, and weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated for each outcome.
resultsSertraline use was associated with significant reductions in body mass index (WMD: − 1.59 kg/m²; 95% CI: − 2.72 to − 0.47; p = 0.005), body weight (BW) (WMD: − 2.21 kg; 95% CI: − 4.40 to − 0.02; p = 0.048), systolic blood pressure (SBP) (WMD: − 3.82 mmHg; 95% CI: − 7.48 to − 0.16; p = 0.041), C-reactive protein(CRP) (WMD: − 0.21 mg/dL; 95% CI: − 0.26 to − 0.16; p < 0.001), interleukin-6 (IL-6) (WMD: − 5.91 pg/ml; 95% CI: − 11.33 to − 0.49; p = 0.032), and glycated hemoglobin (HbA1c) (WMD: − 0.51%; 95% CI: − 0.91 to − 0.11; p = 0.012). No significant effects were observed on fasting blood sugar (FBS), diastolic blood pressure (IL-6), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), or triglyceride (TG) levels. Importantly, lipid endpoint analyses were underpowered, with only two RCTs available for most lipid outcomes and a single RCT for triglycerides, representing a significant evidence gap that limits confidence in these findings. Sensitivity analyses confirmed the robustness of results, and publication bias was minimal.
conclusionSertraline demonstrates beneficial effects on several cardiometabolic markers, including obesity indices, inflammation, glycemic control, and systolic blood pressure, while showing no significant impact on lipid profiles or diastolic blood pressure. These findings suggest that sertraline may offer added clinical value for patients with depression who are also at increased risk of metabolic and cardiovascular complications. However, because most included trials enrolled participants with comorbidities and moderate-to-severe depression, the generalizability of these results to healthier or lower-risk populations remains uncertain. Moreover, the limited number of trials assessing lipid outcomes highlights a critical need for further well-powered RCTs focusing specifically on lipid profiles to conclusively determine sertraline’s effects on lipid metabolism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.